pharma& Announces Health Canada has Accepted for Review the New Drug Submission (NDS) for Rubraca® (rucaparib) in the treatment of Advanced Ovarian Cancer

- Submission supported by positive data from the pivotal Phase 3 ATHENA clinical trial
- Pending approval, potential for marketing authorization in or before December 2026

Intended for the Healthcare Media

Vienna, Austria, February 24, 2026 – pharmaand GmbH (pharma&) announced that Health Canada has accepted for review the New Drug Submission (NDS) for Rubraca® (rucaparib) as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and VI) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. [1]

"We are pleased that Health Canada has accepted the new drug submission. This review is an important milestone in our effort to bring rucaparib treatment as a first-line therapy for a broad population of eligible patients in Canada diagnosed with advanced ovarian cancer," said Frank Rotmann, Co-Founder and Managing Director of pharma&. "We appreciate the opportunity to work with Health Canada in the coming months as they review the application to support this label expansion."

Pending Health Canada's approval of the submission, pharma's Canadian subsidiary, Postera Inc., will be responsible for promoting rucaparib in Canada.

Health Canada's acceptance is based on the results of the international, randomized, double-blind, phase III ATHENA (GOG 3020/ENGOT-ov45) trial. The ATHENA-MONO arm of the trial evaluated rucaparib monotherapy as a maintenance treatment for 538 patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. In the ATHENA-MONO arm of the trial, rucaparib significantly improved investigator-assessed progression-free survival (PFS) compared with placebo in women.[2] The safety profile observed in the ATHENA-MONO trial was consistent with both the current U.S. and European licenses for rucaparib.

About the ATHENA Clinical Trial

ATHENA (GOG 3020/ENGOT-ov45) (NCT03522246) is an international, randomized, double-blind, phase III trial consisting of two separate and fully independently powered study comparisons evaluating rucaparib monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment for patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. ATHENA enrolled approximately 1000 patients across 24 countries, all women with newly diagnosed ovarian

cancer who responded to their first-line chemotherapy. The trial completed accrual in 2020 and was conducted in association with the GOG Foundation, Inc. (GOG-F) in the U.S. and the European Network of Gynaecological Oncological Trial groups (ENGOT) in Europe. GOG-F and ENGOT are the two largest cooperative groups in the U.S. and Europe dedicated to the treatment of gynecological cancers.

ATHENA-MONO is evaluating the benefit of rucaparib monotherapy versus placebo in 538 women in this patient population. The primary efficacy analysis evaluated two prospectively defined molecular sub-groups in a step-down manner: 1) HRD-positive (inclusive of *BRCA* mutant) tumors, and 2) the intent-to-treat population, or all patients treated in ATHENA-MONO

About Ovarian Cancer

Ovarian cancer is the seventh leading cause of cancer-related death among women worldwide. In 2022, the Global Cancer Observatory (GLOBOCAN) estimated that 325,000 women received a new diagnosis of ovarian cancer, and approximately 207,200 women died from ovarian cancer. According to GLOBOCAN in 2022, an estimated 3,300 women in Canada are diagnosed each year with ovarian cancer, and ovarian cancer is among those cancers with the highest rate of deaths. According to the NIH National Cancer Institute, more than 75% of women are diagnosed with ovarian cancer at an advanced stage.

Despite recent advances in the therapeutic landscape of newly diagnosed ovarian cancer, advanced ovarian cancer is still considered incurable for the majority of patients, and the optimal treatment strategy has yet to be determined.i Although most respond initially to this treatment, 80% of patients with advanced ovarian cancer will have a recurrence and require subsequent therapies.[3]

About pharma& (pharmaand.com)

pharmaand GmbH (pharma&), a privately owned global company, aspires to breathe new life into proven medicines. The Company is dedicated to preserving the availability and fostering the further development of essential medicines worldwide to leave no patient behind. pharma& has acquired and integrated 10+ high-need specialty therapeutics, expanding its portfolio across a wide range of therapy areas, with an increasing focus on hematology and oncology treatments. pharma& provides its portfolio of medicines to eligible patients worldwide by spanning the continuum of research and development, in-house product and active pharmaceutical ingredient (API) manufacturing, distribution via its global partner network, healthcare provider engagement, patient safety services, and patient access services.

pharma& cautions that any forward-looking statements or projections made, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. pharma& does not undertake to update or revise any forward-looking statements

###

pharma& Media Contact:
media@pharmaand.com

References

[1] Health Canada Screening Acceptance Letter dated 4 Feb 2026.

[2] Monk BJ et al. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022 Dec 1;40(34):3952-3964.

[3] Hanker LC et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23(10):2605-2612. doi:10.1093/annonc/mds203.